The randomized, placebo-controlled single-dose escalation Phase I study enrolled patients with ATTR into seven sequential cohorts of increasing doses ranging from 0.01 to 1.0mg/kg. Patients administered with ALN-TTR01
Meeting the study’s primary and secondary efficacy endpoints, Prolensa produced statistically greater clearing of subjects’ ocular inflammation by Day 15 and a greater proportion of subjects that were
In a 52-week study in African-American patients with moderate-to-severe persistent asthma, the company found that headache, nasopharyngitis, sinusitis and viral upper respiratory tract infection were the most common
The expanded agreement now includes North and South American territories such as Canada, Mexico and Brazil, in addition to the US. As per the new agreement, Arena is
The acquisition is expected to see the integration of technologies from two companies in product development and marketing to offer customer benefits through complementary product and service solutions.
As per the approval, Cell Therapeutics will be able to market Pixuvri in the 27 Member States of the European Union (EU) as well as in Iceland, Liechtenstein
Cathejell Jelly 2% combines a sterile gel and lidocaine in a collapsible applicator syringe which provides a safe and effective solution for patients to ease the discomfort of
The launch follows the introduction of vitaMedMD One Rx earlier this month and vitaMedMD Plus Rx last month, said the company. vitaMedMD RediChew Rx contains folic acid and
The Mobile Intelligence will serve as a cloud-based service for the pharma company’s sales force and account managers to better control operational efficiency, and improve targeting and segmentation
The companies have kept further terms of the agreement confidential. ZyGEM CEO Paul Kinnon said the RNA extraction technology represents an advance in sample preparation for RNA-based testing
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.